IRIS Accounts Production v23.2.0.158 11080821 Board of Directors Board of Directors Board of Directors 1.7.22 30.6.23 30.6.23 false true false false true false Ordinary A 1.00000 Ordinary B 1.00000 Ordinary C 1.00000 Ordinary D 1.00000 Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure110808212022-06-30110808212023-06-30110808212022-07-012023-06-30110808212021-06-30110808212021-07-012022-06-30110808212022-06-3011080821ns16:EnglandWales2022-07-012023-06-3011080821ns15:PoundSterling2022-07-012023-06-3011080821ns11:Director12022-07-012023-06-3011080821ns11:Director22022-07-012023-06-3011080821ns11:Director32022-07-012023-06-3011080821ns11:PrivateLimitedCompanyLtd2022-07-012023-06-3011080821ns11:SmallEntities2022-07-012023-06-3011080821ns11:AuditExemptWithAccountantsReport2022-07-012023-06-3011080821ns11:SmallCompaniesRegimeForDirectorsReport2022-07-012023-06-3011080821ns11:SmallCompaniesRegimeForAccounts2022-07-012023-06-3011080821ns11:FullAccounts2022-07-012023-06-3011080821ns11:OrdinaryShareClass22022-07-012023-06-3011080821ns11:OrdinaryShareClass32022-07-012023-06-3011080821ns11:OrdinaryShareClass42022-07-012023-06-3011080821ns11:OrdinaryShareClass52022-07-012023-06-3011080821ns11:OrdinaryShareClass12022-07-012023-06-3011080821ns11:CompanySecretary12022-07-012023-06-3011080821ns11:RegisteredOffice2022-07-012023-06-3011080821ns6:CurrentFinancialInstruments2023-06-3011080821ns6:CurrentFinancialInstruments2022-06-3011080821ns6:Non-currentFinancialInstruments2023-06-3011080821ns6:Non-currentFinancialInstruments2022-06-3011080821ns6:ShareCapital2023-06-3011080821ns6:ShareCapital2022-06-3011080821ns6:RetainedEarningsAccumulatedLosses2023-06-3011080821ns6:RetainedEarningsAccumulatedLosses2022-06-3011080821ns6:LeaseholdImprovements2022-07-012023-06-3011080821ns6:PlantMachinery2022-07-012023-06-3011080821ns6:FurnitureFittings2022-07-012023-06-3011080821ns6:MotorVehicles2022-07-012023-06-3011080821ns6:ComputerEquipment2022-07-012023-06-3011080821ns6:LeaseholdImprovements2022-06-3011080821ns6:PlantMachinery2022-06-3011080821ns6:FurnitureFittings2022-06-3011080821ns6:LeaseholdImprovements2023-06-3011080821ns6:PlantMachinery2023-06-3011080821ns6:FurnitureFittings2023-06-3011080821ns6:LeaseholdImprovements2022-06-3011080821ns6:PlantMachinery2022-06-3011080821ns6:FurnitureFittings2022-06-3011080821ns6:MotorVehicles2022-06-3011080821ns6:ComputerEquipment2022-06-3011080821ns6:MotorVehicles2023-06-3011080821ns6:ComputerEquipment2023-06-3011080821ns6:MotorVehicles2022-06-3011080821ns6:ComputerEquipment2022-06-3011080821ns6:PlantMachineryns6:LeasedAssetsHeldAsLessee2022-06-3011080821ns6:PlantMachineryns6:LeasedAssetsHeldAsLessee2022-07-012023-06-3011080821ns6:PlantMachineryns6:LeasedAssetsHeldAsLessee2023-06-3011080821ns6:PlantMachineryns6:LeasedAssetsHeldAsLessee2022-06-3011080821ns6:WithinOneYearns6:CurrentFinancialInstruments2023-06-3011080821ns6:WithinOneYearns6:CurrentFinancialInstruments2022-06-3011080821ns6:WithinOneYearns6:CurrentFinancialInstrumentsns6:HirePurchaseContracts2023-06-3011080821ns6:WithinOneYearns6:CurrentFinancialInstrumentsns6:HirePurchaseContracts2022-06-3011080821ns6:BetweenOneFiveYearsns6:HirePurchaseContracts2023-06-3011080821ns6:BetweenOneFiveYearsns6:HirePurchaseContracts2022-06-3011080821ns6:HirePurchaseContracts2023-06-3011080821ns6:HirePurchaseContracts2022-06-3011080821ns6:WithinOneYear2023-06-3011080821ns6:WithinOneYear2022-06-3011080821ns6:BetweenOneFiveYears2023-06-3011080821ns6:BetweenOneFiveYears2022-06-3011080821ns6:AllPeriods2023-06-3011080821ns6:AllPeriods2022-06-3011080821ns11:OrdinaryShareClass22023-06-3011080821ns11:OrdinaryShareClass32023-06-3011080821ns11:OrdinaryShareClass42023-06-3011080821ns11:OrdinaryShareClass52023-06-30
REGISTERED NUMBER: 11080821 (England and Wales)






















Unaudited Financial Statements

for the Year Ended 30 June 2023

for

Biospectrum Limited

Biospectrum Limited (Registered number: 11080821)






Contents of the Financial Statements
for the Year Ended 30 June 2023




Page

Company Information 1

Chartered Accountants' Report 2

Balance Sheet 3

Notes to the Financial Statements 5


Biospectrum Limited

Company Information
for the Year Ended 30 June 2023







DIRECTORS: Mrs P A McQuilkin
A P McQuilkin
B Lamper





SECRETARY: Mrs P A McQuilkin





REGISTERED OFFICE: Unit 9
Halifax Court
Fernwood Business Park
Newark
Nottinghamshire
NG24 3JP





REGISTERED NUMBER: 11080821 (England and Wales)





ACCOUNTANTS: Wright Vigar Limited
Chartered Accountants & Business Advisers
Chancery Court
34 West Street
Retford
Nottinghamshire
DN22 6ES

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Biospectrum Limited

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Biospectrum Limited for the year ended 30 June 2023 which comprise the Income Statement, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Biospectrum Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Biospectrum Limited and state those matters that we have agreed to state to the Board of Directors of Biospectrum Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Biospectrum Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Biospectrum Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Biospectrum Limited. You consider that Biospectrum Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Biospectrum Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Wright Vigar Limited
Chartered Accountants & Business Advisers
Chancery Court
34 West Street
Retford
Nottinghamshire
DN22 6ES


20 September 2023

Biospectrum Limited (Registered number: 11080821)

Balance Sheet
30 June 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 80,308 65,019

CURRENT ASSETS
Stocks 279,462 258,992
Debtors 5 280,756 195,577
Cash at bank and in hand 98,336 26,459
658,554 481,028
CREDITORS
Amounts falling due within one year 6 293,077 234,825
NET CURRENT ASSETS 365,477 246,203
TOTAL ASSETS LESS CURRENT
LIABILITIES

445,785

311,222

CREDITORS
Amounts falling due after more than one
year

7

(30,468

)

(41,911

)

PROVISIONS FOR LIABILITIES (11,375 ) (7,631 )
NET ASSETS 403,942 261,680

CAPITAL AND RESERVES
Called up share capital 9 136 117
Retained earnings 403,806 261,563
SHAREHOLDERS' FUNDS 403,942 261,680

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Biospectrum Limited (Registered number: 11080821)

Balance Sheet - continued
30 June 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 September 2023 and were signed on its behalf by:




A P McQuilkin - Director Mrs P A McQuilkin - Director




B Lamper - Director


Biospectrum Limited (Registered number: 11080821)

Notes to the Financial Statements
for the Year Ended 30 June 2023

1. STATUTORY INFORMATION

Biospectrum Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
Improvements to property - 20% on cost
Plant and machinery - 20% on cost
Fixtures and fittings - 25% on reducing balance
Motor vehicles - 20% on cost
Computer equipment - 33% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Biospectrum Limited (Registered number: 11080821)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2023

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2022 - 6 ) .

4. TANGIBLE FIXED ASSETS
Improvements Fixtures
to Plant and and
property machinery fittings
£    £    £   
COST
At 1 July 2022 8,823 33,146 3,848
Additions - 29,022 603
Disposals - - -
At 30 June 2023 8,823 62,168 4,451
DEPRECIATION
At 1 July 2022 4,080 4,072 1,864
Charge for year 1,765 10,197 551
Eliminated on disposal - - -
At 30 June 2023 5,845 14,269 2,415
NET BOOK VALUE
At 30 June 2023 2,978 47,899 2,036
At 30 June 2022 4,743 29,074 1,984

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 July 2022 36,499 3,057 85,373
Additions 14,750 2,357 46,732
Disposals (17,000 ) - (17,000 )
At 30 June 2023 34,249 5,414 115,105
DEPRECIATION
At 1 July 2022 8,188 2,150 20,354
Charge for year 7,128 1,099 20,740
Eliminated on disposal (6,297 ) - (6,297 )
At 30 June 2023 9,019 3,249 34,797
NET BOOK VALUE
At 30 June 2023 25,230 2,165 80,308
At 30 June 2022 28,311 907 65,019

Biospectrum Limited (Registered number: 11080821)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2023

4. TANGIBLE FIXED ASSETS - continued

Fixed assets, included in the above, which are held under hire purchase contracts are as follows:

Plant and
machinery
etc
£   
COST
At 1 July 2022 34,000
Additions 14,750
Disposals (17,000 )
At 30 June 2023 31,750
DEPRECIATION
At 1 July 2022 7,182
Charge for year 6,628
Eliminated on disposal (6,297 )
At 30 June 2023 7,513
NET BOOK VALUE
At 30 June 2023 24,237
At 30 June 2022 26,818

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 217,311 136,459
Other debtors 63,445 59,118
280,756 195,577

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Bank loans and overdrafts 10,000 10,000
Hire purchase contracts (see note 8) 4,928 6,430
Trade creditors 43,358 116,399
Taxation and social security 120,685 48,998
Other creditors 114,106 52,998
293,077 234,825

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2023 2022
£    £   
Bank loans 19,167 29,167
Hire purchase contracts (see note 8) 11,301 12,744
30,468 41,911

Biospectrum Limited (Registered number: 11080821)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2023

8. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase contracts
2023 2022
£    £   
Net obligations repayable:
Within one year 4,928 6,430
Between one and five years 11,301 12,744
16,229 19,174

Non-cancellable operating leases
2023 2022
£    £   
Within one year 22,000 22,000
Between one and five years 88,000 88,000
110,000 110,000

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
70 Ordinary A £1 70 -
33 Ordinary B £1 33 -
30 Ordinary C £1 30 -
3 Ordinary D £1 3 -
136 -

Allotted and issued:
Number: Class: Nominal 2023 2022
value: £    £   
NIL Ordinary £1 - 117